Register for our free email digests:
Division of Pfizer Inc.
Latest From Monsanto Co.
Bayer AG may more often make headlines for its deal-making in consumer health and agriculture, but the massive German conglomerate sees oncology drugs as a key engine of future success within its high-growth pharmaceuticals business. A Q&A with Robert LaCaze, EVP of Bayer's new Oncology Strategic Business Unit.
The still pending acquisition of Monsanto, crop science problems in Brazil and a weak showing from consumer health in the US cannot disguise the strong growth that Bayer's pharmaceuticals business is continuing to enjoy.
Bayer consumer readies 19-product pipeline for 2017 as it works to increase sales of brands including Coppertone and Dr. Scholl’s brands that have been sluggish since being acquired from Merck & Co.
Big pharma is poised to dominate deal-making this year while the firepower of specialty pharma to do deals has waned. 2017 could be a record year for M&A, EY predicts in its annual M&A Outlook and Fire Power Report.
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Pfizer Inc.
- Senior Management
Terry Crews, CFO
Robb Fraley, CTO
Hugh Grant, COO
William Ide, SVP
- Contact Info
Phone: (314) 694-1000
800 North Lindbergh Boulevard
St. Louis, MO 63167
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.